

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person * <u>Rasmussen Torsten</u> (Last) (First) (Middle) 11085 TORREYANA ROAD #100 (Street) SAN DIEGO CA 92121 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol ACADIA PHARMACEUTICALS INC [ACAD]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 05/01/2014	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	05/01/2014		M		6,500	A	\$8.85	15,000	I	See footnote ⁽¹⁾
Common Stock	05/01/2014		M		2,542	A	\$8.85	17,542	I	See footnote ⁽¹⁾
Common Stock	05/01/2014		M		8,500	A	\$11	26,042	I	See footnote ⁽¹⁾
Common Stock	05/01/2014		M		10,000	A	\$9.04	36,042	I	See footnote ⁽¹⁾
Common Stock	05/01/2014		M		5,315	A	\$15.02	41,357	I	See footnote ⁽¹⁾
Common Stock	05/01/2014		S ⁽²⁾		32,857	D	\$20.0333 ⁽³⁾	8,500	I	See footnote ⁽¹⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Stock option (right to buy)	\$8.85	05/01/2014		M			6,500	(4)	06/09/2015	Common Stock	6,500	\$0	0	I	See footnote ⁽¹⁾
Stock option (right to buy)	\$8.85	05/01/2014		M			2,542	(4)	06/09/2015	Common Stock	2,542	\$0	0	I	See footnote ⁽¹⁾
Stock option (right to buy)	\$11	05/01/2014		M			8,500	(5)	09/08/2015	Common Stock	8,500	\$0	0	I	See footnote ⁽¹⁾
Stock option (right to buy)	\$9.04	05/01/2014		M			10,000	(6)	06/12/2016	Common Stock	10,000	\$0	0	I	See footnote ⁽¹⁾
Stock option (right to buy)	\$15.02	05/01/2014		M			5,315	(7)	06/14/2017	Common Stock	5,315	\$0	4,685	I	See footnote ⁽¹⁾

Explanation of Responses:

- Shares and options are held by Morgan Management Aps, a Danish corporation in which Mr. Rasmussen has a controlling interest.
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in June 2013.
- The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from \$19.55 to \$20.32 per share, inclusive. The reporting person undertakes to

provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.

4. 25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 10, 2005.
5. 25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of September 9, 2005.
6. 25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2006.
7. 25% of the shares subject to the stock option vested and became exercisable at the end of each 3-month period following the date of grant of June 15, 2007.

/s/ Glenn F. Baity, Attorney-in-Fact 05/02/2014

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.